Proteomic Analysis of Neuroblastoma Subtypes in Response to Mitogen-Activated Protein Kinase Inhibition: Profiling Multiple Targets of Cancer Kinase Signaling

John A. Sandoval, Andrew Eppstein, Derek J. Hoelz, Patrick J. Klein, Jared H. Linebarger, Katharyn E. Turner, Frederick Rescorla, Robert J. Hickey, Linda H. Malkas, C. Schmidt

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Survival for high-risk neuroblastoma (NB) remains poor despite aggressive therapy. Novel therapies are vital for improving prognosis. We previously showed differential NB subtype sensitivity to p42/44 mitogen-activated protein kinase (ERK/MAPK) pathway inhibition. In this study, we investigated proteomic changes associated with resistance or sensitivity to MAPK kinase (MEK) inhibition in NB subtypes. Materials and Methods: SH-SY5Y (N-type), BE(2)-C (I-type), and SK-N-AS (S-type) were treated with MEK inhibitor U0126 (10 μM) for 1 and 24 h. Proteins were extracted from untreated and treated cells and analyzed for differential expression by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE). Selected polypeptides were extracted from the gel and identified by liquid chromatography-linked tandem mass spectrometry (LC-MS/MS). Results: We identified 15 proteins that were decreased by 2.5-fold between untreated and 1 h treated cells and subsequently up-regulated 5-fold after 24 h drug treatment. N-type NB (MEK-resistant) showed the least altered proteomic profile whereas the I-type (MEK-sensitive) and S-type NB (MEK-intermediate) generated significant protein changes. The majority of proteins identified were induced by stress. Conclusions: Protein differences exist between MEK inhibitor-treated NB subtypes. Identified polypeptides all have roles in mediating cellular stress. These data suggest that inhibition of the ERK/MAPK in NB subtypes leads to an intracellular stress response. The most resistant NB cell line to MEK inhibitor treatment generated the least protective protein profile, whereas the intermediate and most sensitive NB cells produced the most stress response. These findings suggest stress related protein expression may be targeted in assessing a response to ERK/MAPK therapeutics.

Original languageEnglish
Pages (from-to)61-67
Number of pages7
JournalJournal of Surgical Research
Volume134
Issue number1
DOIs
StatePublished - Jul 2006

Fingerprint

Mitogen-Activated Protein Kinases
Neuroblastoma
Mitogen-Activated Protein Kinase Kinases
Proteomics
Phosphotransferases
Neoplasms
Proteins
Electrophoresis, Gel, Two-Dimensional
Peptides
MAP Kinase Signaling System
Mitogen-Activated Protein Kinase 1
Heat-Shock Proteins
Tandem Mass Spectrometry
Liquid Chromatography
Therapeutics
Gels
Cell Line
Pharmaceutical Preparations

Keywords

  • cell stress
  • drug sentivity/resistance
  • ERK/MAPK
  • I-type
  • MEK inhibition
  • N-type
  • neuroblastoma
  • proteomics
  • S-type
  • U0126

ASJC Scopus subject areas

  • Surgery

Cite this

Proteomic Analysis of Neuroblastoma Subtypes in Response to Mitogen-Activated Protein Kinase Inhibition : Profiling Multiple Targets of Cancer Kinase Signaling. / Sandoval, John A.; Eppstein, Andrew; Hoelz, Derek J.; Klein, Patrick J.; Linebarger, Jared H.; Turner, Katharyn E.; Rescorla, Frederick; Hickey, Robert J.; Malkas, Linda H.; Schmidt, C.

In: Journal of Surgical Research, Vol. 134, No. 1, 07.2006, p. 61-67.

Research output: Contribution to journalArticle

Sandoval, John A. ; Eppstein, Andrew ; Hoelz, Derek J. ; Klein, Patrick J. ; Linebarger, Jared H. ; Turner, Katharyn E. ; Rescorla, Frederick ; Hickey, Robert J. ; Malkas, Linda H. ; Schmidt, C. / Proteomic Analysis of Neuroblastoma Subtypes in Response to Mitogen-Activated Protein Kinase Inhibition : Profiling Multiple Targets of Cancer Kinase Signaling. In: Journal of Surgical Research. 2006 ; Vol. 134, No. 1. pp. 61-67.
@article{7fb68bec13e1455b945dbd97b9fc067a,
title = "Proteomic Analysis of Neuroblastoma Subtypes in Response to Mitogen-Activated Protein Kinase Inhibition: Profiling Multiple Targets of Cancer Kinase Signaling",
abstract = "Introduction: Survival for high-risk neuroblastoma (NB) remains poor despite aggressive therapy. Novel therapies are vital for improving prognosis. We previously showed differential NB subtype sensitivity to p42/44 mitogen-activated protein kinase (ERK/MAPK) pathway inhibition. In this study, we investigated proteomic changes associated with resistance or sensitivity to MAPK kinase (MEK) inhibition in NB subtypes. Materials and Methods: SH-SY5Y (N-type), BE(2)-C (I-type), and SK-N-AS (S-type) were treated with MEK inhibitor U0126 (10 μM) for 1 and 24 h. Proteins were extracted from untreated and treated cells and analyzed for differential expression by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE). Selected polypeptides were extracted from the gel and identified by liquid chromatography-linked tandem mass spectrometry (LC-MS/MS). Results: We identified 15 proteins that were decreased by 2.5-fold between untreated and 1 h treated cells and subsequently up-regulated 5-fold after 24 h drug treatment. N-type NB (MEK-resistant) showed the least altered proteomic profile whereas the I-type (MEK-sensitive) and S-type NB (MEK-intermediate) generated significant protein changes. The majority of proteins identified were induced by stress. Conclusions: Protein differences exist between MEK inhibitor-treated NB subtypes. Identified polypeptides all have roles in mediating cellular stress. These data suggest that inhibition of the ERK/MAPK in NB subtypes leads to an intracellular stress response. The most resistant NB cell line to MEK inhibitor treatment generated the least protective protein profile, whereas the intermediate and most sensitive NB cells produced the most stress response. These findings suggest stress related protein expression may be targeted in assessing a response to ERK/MAPK therapeutics.",
keywords = "cell stress, drug sentivity/resistance, ERK/MAPK, I-type, MEK inhibition, N-type, neuroblastoma, proteomics, S-type, U0126",
author = "Sandoval, {John A.} and Andrew Eppstein and Hoelz, {Derek J.} and Klein, {Patrick J.} and Linebarger, {Jared H.} and Turner, {Katharyn E.} and Frederick Rescorla and Hickey, {Robert J.} and Malkas, {Linda H.} and C. Schmidt",
year = "2006",
month = "7",
doi = "10.1016/j.jss.2006.02.011",
language = "English",
volume = "134",
pages = "61--67",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Proteomic Analysis of Neuroblastoma Subtypes in Response to Mitogen-Activated Protein Kinase Inhibition

T2 - Profiling Multiple Targets of Cancer Kinase Signaling

AU - Sandoval, John A.

AU - Eppstein, Andrew

AU - Hoelz, Derek J.

AU - Klein, Patrick J.

AU - Linebarger, Jared H.

AU - Turner, Katharyn E.

AU - Rescorla, Frederick

AU - Hickey, Robert J.

AU - Malkas, Linda H.

AU - Schmidt, C.

PY - 2006/7

Y1 - 2006/7

N2 - Introduction: Survival for high-risk neuroblastoma (NB) remains poor despite aggressive therapy. Novel therapies are vital for improving prognosis. We previously showed differential NB subtype sensitivity to p42/44 mitogen-activated protein kinase (ERK/MAPK) pathway inhibition. In this study, we investigated proteomic changes associated with resistance or sensitivity to MAPK kinase (MEK) inhibition in NB subtypes. Materials and Methods: SH-SY5Y (N-type), BE(2)-C (I-type), and SK-N-AS (S-type) were treated with MEK inhibitor U0126 (10 μM) for 1 and 24 h. Proteins were extracted from untreated and treated cells and analyzed for differential expression by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE). Selected polypeptides were extracted from the gel and identified by liquid chromatography-linked tandem mass spectrometry (LC-MS/MS). Results: We identified 15 proteins that were decreased by 2.5-fold between untreated and 1 h treated cells and subsequently up-regulated 5-fold after 24 h drug treatment. N-type NB (MEK-resistant) showed the least altered proteomic profile whereas the I-type (MEK-sensitive) and S-type NB (MEK-intermediate) generated significant protein changes. The majority of proteins identified were induced by stress. Conclusions: Protein differences exist between MEK inhibitor-treated NB subtypes. Identified polypeptides all have roles in mediating cellular stress. These data suggest that inhibition of the ERK/MAPK in NB subtypes leads to an intracellular stress response. The most resistant NB cell line to MEK inhibitor treatment generated the least protective protein profile, whereas the intermediate and most sensitive NB cells produced the most stress response. These findings suggest stress related protein expression may be targeted in assessing a response to ERK/MAPK therapeutics.

AB - Introduction: Survival for high-risk neuroblastoma (NB) remains poor despite aggressive therapy. Novel therapies are vital for improving prognosis. We previously showed differential NB subtype sensitivity to p42/44 mitogen-activated protein kinase (ERK/MAPK) pathway inhibition. In this study, we investigated proteomic changes associated with resistance or sensitivity to MAPK kinase (MEK) inhibition in NB subtypes. Materials and Methods: SH-SY5Y (N-type), BE(2)-C (I-type), and SK-N-AS (S-type) were treated with MEK inhibitor U0126 (10 μM) for 1 and 24 h. Proteins were extracted from untreated and treated cells and analyzed for differential expression by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE). Selected polypeptides were extracted from the gel and identified by liquid chromatography-linked tandem mass spectrometry (LC-MS/MS). Results: We identified 15 proteins that were decreased by 2.5-fold between untreated and 1 h treated cells and subsequently up-regulated 5-fold after 24 h drug treatment. N-type NB (MEK-resistant) showed the least altered proteomic profile whereas the I-type (MEK-sensitive) and S-type NB (MEK-intermediate) generated significant protein changes. The majority of proteins identified were induced by stress. Conclusions: Protein differences exist between MEK inhibitor-treated NB subtypes. Identified polypeptides all have roles in mediating cellular stress. These data suggest that inhibition of the ERK/MAPK in NB subtypes leads to an intracellular stress response. The most resistant NB cell line to MEK inhibitor treatment generated the least protective protein profile, whereas the intermediate and most sensitive NB cells produced the most stress response. These findings suggest stress related protein expression may be targeted in assessing a response to ERK/MAPK therapeutics.

KW - cell stress

KW - drug sentivity/resistance

KW - ERK/MAPK

KW - I-type

KW - MEK inhibition

KW - N-type

KW - neuroblastoma

KW - proteomics

KW - S-type

KW - U0126

UR - http://www.scopus.com/inward/record.url?scp=33744977407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744977407&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2006.02.011

DO - 10.1016/j.jss.2006.02.011

M3 - Article

C2 - 16650873

AN - SCOPUS:33744977407

VL - 134

SP - 61

EP - 67

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -